1. In Vivo
  2. >>Archive

Exact Sciences Buys Time with Genzyme Deal

On the heels of its rejection of a buyout from Sequenom, Exact Sciences announced a $24.5 million IP licensing deal with Genzyme. The transaction effectively halted Sequenom's takeover effort and bought Exact time for clinical development of a next-generation version of its stool-based colorectal cancer screening test. It'sa hefty deal, but Exact's path to sustainability remains problematic.

In late January, on the heels of its rejection of a buyout from Sequenom Inc. worth approximately $41 million [See Deal], Exact Sciences Corp. announced a $24.5 million intellectual property licensing deal with Genzyme Corp. The transaction effectively halted Sequenom’s takeover effort and bought Exact time for product development, which had stalled last year when the company was forced to cut back its operations. It’s a hefty deal, but Exact’s path to sustainability remains problematic.

In exchange for $16.65 million in cash upfront and $1.85 million over the next year-and-a-half, plus a $6 million equity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.